Fig. 1From: Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemiaApatinib exhibits a dose- and time-dependent inhibition of proliferation of B and T-lineage ALL cell lines. B-lineage (a, b) and T-lineage ALL cells (c, d) were exposed to indicated concentrations of Apatinib for 48 or 72 h, and cell viability was subsequently determined by a CCK-8 kitBack to article page